A groundbreaking investigation, utilizing advanced intracranial electroencephalography (iEEG) in a volunteer with severe obesity and a history of uncontrolled eating, has provided unprecedented insights into the neurological mechanisms by which the dual-acting medication tirzepatide (marketed as Mounjaro and Zepbound) influences brain activity associated with food cravings. The recorded neural data revealed a significant suppression of activity within the brain’s reward circuitry, a key area implicated in what is often described as "food noise" and the overwhelming compulsion to eat. However, this inhibitory effect demonstrated a notable lack of permanence, with the neural signals indicative of craving ultimately re-emerging.
Researchers elucidated that tirzepatide functions as an agonist for both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, a pharmacological profile initially developed for the management of Type 2 diabetes. Emerging evidence now suggests its potential utility in addressing impulse control disorders, including binge eating disorder. Nevertheless, the contemporary findings, detailed in a recent report from the Perelman School of Medicine at the University of Pennsylvania, underscore the necessity for further scrutiny, indicating that current formulations of GLP-1 and GIP receptor agonists may not be fully optimized for the comprehensive treatment of these behavioral conditions. This significant case study has been published in the esteemed journal Nature Medicine.
"This investigation offers profound insights into the potential brain-based mechanisms of action for these pharmacological agents and will serve as a crucial guide as we expand our exploration into new therapeutic applications," stated senior author Dr. Casey H. Halpern, a distinguished professor of Neurosurgery and the director of the Division of Stereotactic and Functional Neurosurgery. "Until we achieve a more comprehensive understanding of their intricate effects on the human brain, it remains premature to categorize GLP-1 and GIP receptor agonists as universally effective treatments for conditions beyond their established indications of type 2 diabetes and obesity."
Understanding the Phenomenon of Loss of Control Eating and Pervasive Food Thoughts
The experience of loss of control eating is a widespread challenge, impacting a substantial proportion of individuals grappling with obesity, as well as those diagnosed with various eating disorders. Binge eating disorder (BED), recognized as the most prevalent eating disorder within the United States, affects an estimated population exceeding 3 million individuals. Those affected by BED frequently report an inability to cease eating, continuing to consume food well beyond the point of satiety.
Central to the regulation of eating behaviors are critical brain regions, including the hypothalamus and the nucleus accumbens (NAc). The NAc, in particular, functions as a pivotal component of the brain’s reward system, playing a significant role in governing motivation, the pursuit of pleasure, and the capacity for impulse control. Scientific studies have consistently demonstrated that in individuals experiencing obesity and BED, the signaling pathways within the NAc and its interconnected neural networks exhibit significant dysregulation.
Even in the absence of a formal BED diagnosis, up to 60 percent of individuals classified as having obesity report experiencing persistent "food noise." This phenomenon is characterized by an incessant stream of intrusive thoughts concerning food, which can precipitate considerable psychological distress and foster maladaptive eating patterns, such as bingeing or episodes of loss of control eating. Food noise is also a commonly reported symptom in individuals with bulimia nervosa and anorexia nervosa. Furthermore, research has established a correlation between binge eating behaviors and an elevated risk of suicidal ideation among individuals with obesity and eating disorders, a link that is likely attributable to underlying traits of impulsivity and difficulties with emotional regulation.
"The development of novel therapeutic strategies for this patient population is of paramount importance," emphasized Dr. Halpern. "While a considerable number of individuals undergoing treatment with GLP-1 and GIP receptor agonists report a discernible reduction in food noise, it is crucial to note that these medications are not presently approved by the FDA for the treatment of food preoccupation and its associated impulsivity. In fact, their direct impact on human brain activity has only recently begun to be systematically investigated."
A Patient’s Experience Navigating Severe Obesity and Persistent Food Noise
The case study focused on a 60-year-old woman, identified within the research as "Participant 3," who presented with severe, treatment-resistant obesity and a persistent and debilitating condition of food noise. She described a continuous barrage of intrusive thoughts about food, which frequently compelled her to order takeout meals or engage in snacking throughout the day, even when she actively attempted to refrain. Her eating episodes often extended until she experienced significant physical discomfort from overconsumption, with a particular predilection for high-sugar and high-salt items, such as commercially packaged cupcakes, fast-food roast beef sandwiches, and French fries. In addition to her obesity, she also managed Type-2 diabetes. Previously, she had been prescribed dulaglutide, a GLP-1 receptor agonist, which unfortunately yielded no discernible impact on her body weight or her obsessive preoccupation with food.
Following an extensive history of attempted treatments, including bariatric surgery, various pharmacological interventions, behavioral therapy, and other specialized approaches for disordered eating, she volunteered to participate in Dr. Halpern’s clinical trial. The study’s methodology involved a neurosurgical procedure to implant electrodes designed with the future potential to detect and intercept cravings before they escalated into overt binge eating episodes.
Unraveling the Neural Signatures of Craving Onset
Previous research conducted by Dr. Halpern’s team identified a distinct pattern of electrical activity within the NAc that reliably precedes the onset of food fixation and the subsequent urge to binge. This specific neural signature is differentiated from the activity observed during normal physiological hunger preceding a typical meal. A prior pilot trial, also led by Dr. Halpern, demonstrated that the targeted delivery of high-frequency electrical stimulation to the NAc, precisely synchronized with the emergence of these craving-related neural signals, could effectively interrupt and prevent binge eating behavior.
In the current study, which involved four participants diagnosed with obesity and loss of control eating, iEEG electrodes were surgically implanted. This sophisticated neurophysiological monitoring system, analogous to those employed in the management of epilepsy and Parkinson’s disease, was capable of recording neural activity within the NAc as participants were exposed to specific foods known to trigger their binge episodes.
After establishing a comprehensive baseline of each individual’s neural responses, the research team meticulously programmed the implanted electrodes to deliver high-frequency stimulation upon the detection of these identified craving-related signals. Over a six-month observation period, participants reported substantial reductions in their subjective experiences of loss of control and a significant decrease in the frequency of binge eating episodes.
Tirzepatide Offers a Unique Window into Neural Mechanisms
Prior to undergoing the neurosurgical implantation procedure, Participant 3 was prescribed tirzepatide to manage her Type-2 diabetes, following the unsuccessful trial of a different GLP-1 receptor agonist. Her dosage was progressively increased to the maximum therapeutic level, both before and after the electrode implantation, a measure taken to mitigate potential infection risks associated with surgery in diabetic patients. This clinical circumstance created an exceptionally rare opportunity for researchers to observe, in real-time, the impact of tirzepatide on neural signals directly linked to food cravings.
"The invasive nature of brain surgery required for electrode implantation makes the direct study of human brain activity in this manner exceptionally uncommon," explained Dr. Halpern. "Research endeavors are inherently iterative, and this participant was already receiving tirzepatide upon her enrollment in the trial, prior to the initiation of any electrical stimulation. This provided us with an invaluable opportunity to gather foundational observations regarding how this medication modulates neural signals."
The Transient Nature of Tirzepatide’s Effects on Cravings
Following Participant 3’s attainment of her full tirzepatide dosage and the successful implantation of the electrodes, she reported a complete absence of food preoccupation, and her NAc activity mirrored this neurological quietude. However, approximately five months into the study, a noticeable resurgence of NAc activity, accompanied by the return of intense food noise, was observed. This temporal shift strongly suggested that the suppressive effect of tirzepatide on her loss of control eating was not enduring and that the underlying neural patterns associated with food preoccupation had re-emerged.
In contrast, other participants in the trial who were not taking tirzepatide consistently exhibited heightened NAc activity and frequent episodes of food preoccupation, findings that were consistent with prior observations from Dr. Halpern’s research group. The dramatic reduction in neural signaling exclusively observed in Participant 3 provided compelling evidence that tirzepatide had indeed temporarily suppressed this specific brain activity.
"GLP-1 and GIP receptor agonists are remarkable medications, excelling in their intended applications—managing blood glucose levels in individuals with type 2 diabetes and facilitating weight loss in obesity," commented study investigator Dr. Kelly Allison, a professor of Psychiatry and the Director of the Center for Weight and Eating Disorders. "This research indicates that they may hold promise for managing food preoccupation and binge eating, but likely not in their current therapeutic formulations."
"Although this study’s data regarding tirzepatide’s effects is derived from a single participant, it provides robust evidence illustrating how GLP-1 and GIP receptor agonists can alter electrical signaling within the brain," stated co-first author Wonkyung Choi, a PhD candidate in Dr. Halpern’s laboratory. "These generated insights should serve as a powerful impetus for further research aimed at developing a therapeutic intervention that is more precisely tailored to address the impulsivity traits characteristic of obesity and related eating disorders, while ensuring both safety and long-term efficacy."
This research initiative was generously supported by funding from the National Institutes of Health, through grants including 7UH3NS103446-03, 1R01MH124760-01A1, R25MH119043, and T32NS091008.
About the Author
